JP2014520784A - 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 - Google Patents

抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 Download PDF

Info

Publication number
JP2014520784A
JP2014520784A JP2014517813A JP2014517813A JP2014520784A JP 2014520784 A JP2014520784 A JP 2014520784A JP 2014517813 A JP2014517813 A JP 2014517813A JP 2014517813 A JP2014517813 A JP 2014517813A JP 2014520784 A JP2014520784 A JP 2014520784A
Authority
JP
Japan
Prior art keywords
sequence
region
csf
antibody
antibody specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014517813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520784A5 (https=
Inventor
シュタイドル，シュテファン
Original Assignee
モルフォシス・アー・ゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォシス・アー・ゲー filed Critical モルフォシス・アー・ゲー
Publication of JP2014520784A publication Critical patent/JP2014520784A/ja
Publication of JP2014520784A5 publication Critical patent/JP2014520784A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
JP2014517813A 2011-07-06 2012-07-06 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 Pending JP2014520784A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161504744P 2011-07-06 2011-07-06
US61/504,744 2011-07-06
EP11172865 2011-07-06
EP11172865.5 2011-07-06
PCT/EP2012/063207 WO2013004806A1 (en) 2011-07-06 2012-07-06 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2014520784A true JP2014520784A (ja) 2014-08-25
JP2014520784A5 JP2014520784A5 (https=) 2015-08-13

Family

ID=47436548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517813A Pending JP2014520784A (ja) 2011-07-06 2012-07-06 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用

Country Status (10)

Country Link
US (1) US20140234298A1 (https=)
EP (1) EP2729498A1 (https=)
JP (1) JP2014520784A (https=)
KR (1) KR20140061379A (https=)
CN (1) CN103827143A (https=)
AU (2) AU2012280267B2 (https=)
BR (1) BR112013033944A2 (https=)
CA (1) CA2839513A1 (https=)
RU (1) RU2013156435A (https=)
WO (1) WO2013004806A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525339A (ja) * 2015-06-24 2018-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345923A1 (en) 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
WO2016079276A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
EP3108897A1 (en) * 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
WO2018045117A1 (en) * 2016-09-01 2018-03-08 The Regents Of The University Of Colorado, A Body Corporate Methods of treating eosinophilic gastrointestinal diseases
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3691663A4 (en) 2017-10-02 2021-08-18 Humanigen, Inc. METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN112805301B (zh) 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
SG11202103589XA (en) * 2018-10-31 2021-05-28 Humanigen Inc Materials and methods for treating cancer
US20220010007A1 (en) * 2018-11-09 2022-01-13 Kiniksa Pharmaeuticals, Ltd. Treatment for Giant Cell Arteritis
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US20220202967A1 (en) * 2019-04-25 2022-06-30 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023546657A (ja) * 2020-10-26 2023-11-07 キニクサ ファーマシューティカルズ， リミテッド Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
WO2022225329A1 (ko) * 2021-04-20 2022-10-27 고려대학교 산학협력단 향상된 암세포 사멸효능을 갖는 비대칭 항체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545958A (ja) * 2005-05-20 2008-12-18 ジェネンテック・インコーポレーテッド 自己免疫性疾患の被検体の生体試料の前処理
JP2008545632A (ja) * 2005-05-18 2008-12-18 モルフォシス・アクチェンゲゼルシャフト 抗ｇｍ−ｃｓｆ抗体とその使用
JP2009526082A (ja) * 2006-02-08 2009-07-16 モルフォテック、インク． 抗原性ｇｍ−ｃｓｆペプチドおよび抗ｇｍ−ｃｓｆ抗体
WO2010093480A2 (en) * 2009-02-16 2010-08-19 Biolex Therapeutics, Inc. Humanized anti-cd20 antibodies and methods of use
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
WO2010124163A2 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP1131093A4 (en) 1998-11-09 2002-05-02 Idec Pharma Corp TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
HU229520B1 (en) 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008141391A1 (en) 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
PE20091420A1 (es) 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
NZ588850A (en) 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
KR101681331B1 (ko) 2008-04-29 2016-12-01 암젠 리서치 (뮌헨) 게엠베하 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
US20100122819A1 (en) 2008-11-17 2010-05-20 Baker Hughes Incorporated Inserts with Swellable Elastomer Seals for Side Pocket Mandrels
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545632A (ja) * 2005-05-18 2008-12-18 モルフォシス・アクチェンゲゼルシャフト 抗ｇｍ−ｃｓｆ抗体とその使用
JP2008545958A (ja) * 2005-05-20 2008-12-18 ジェネンテック・インコーポレーテッド 自己免疫性疾患の被検体の生体試料の前処理
JP2009526082A (ja) * 2006-02-08 2009-07-16 モルフォテック、インク． 抗原性ｇｍ−ｃｓｆペプチドおよび抗ｇｍ−ｃｓｆ抗体
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
WO2010093480A2 (en) * 2009-02-16 2010-08-19 Biolex Therapeutics, Inc. Humanized anti-cd20 antibodies and methods of use
WO2010124163A2 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM. J. RESPIR. CRIT. CARE MED., vol. 182, no. 1, JPN6016015786, 2010, pages 49 - 61, ISSN: 0003307913 *
J. IMMUNOL., vol. 164, no. 7, JPN6016015785, 2000, pages 3887 - 3893, ISSN: 0003307912 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525339A (ja) * 2015-06-24 2018-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体

Also Published As

Publication number Publication date
BR112013033944A2 (pt) 2017-12-19
EP2729498A1 (en) 2014-05-14
AU2012280267B2 (en) 2016-04-21
RU2013156435A (ru) 2015-08-20
AU2016201736A1 (en) 2016-04-07
KR20140061379A (ko) 2014-05-21
US20140234298A1 (en) 2014-08-21
CN103827143A (zh) 2014-05-28
AU2012280267A1 (en) 2014-01-16
WO2013004806A1 (en) 2013-01-10
CA2839513A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
AU2012280267B2 (en) Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
JP6486887B2 (ja) 皮下投与される抗ｉｌ−６受容体抗体
EP3747464B1 (en) Methods for treating progressive multiple sclerosis using an anti-cd20 antibody
US20240366756A1 (en) Combinations and uses thereof
JP7288927B2 (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用
CN102512675A (zh) 用于治疗多发性硬化的方法
CN101027100A (zh) 治疗干燥综合征的方法
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2017519757A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置
KR20230045613A (ko) Covid-19의 치료 및 예방을 위한 sars-cov-2 항체
US20190322734A1 (en) Treatment paradigm
JP2024525870A (ja) 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療
CN108431038A (zh) 治疗多发性硬化的方法
JPWO2023031403A5 (https=)
US20240270862A1 (en) Use of b cell depleting agents for the treatment of rheumatic heart disease
US20250134997A1 (en) Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy in ctdna high risk patients
WO2025215124A2 (en) Combination treatment of glofitamab and chemotherapy
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
WO2025222102A1 (en) Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies
CN118076640A (zh) 抗-pla2r自身抗体介导的膜性肾病的治疗
JP2020055830A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170110